Fonar Corporation
| NASDAQ: FONR | Healthcare / Medical Devices & Instruments / USA |
| 19.47 | +0.1000 | +0.52% | Vol 13.80K | 1Y Perf 9.19% |
| Dec 6th, 2023 16:00 DELAYED |
| BID | 18.90 | ASK | 20.02 | ||
| Open | 19.45 | Previous Close | 19.37 | ||
| Pre-Market | - | After-Market | 19.47 | ||
| - - | - -% |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★★ 62.51 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★★+ 62.83 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 91.18 | Earnings Rating | Neutral | |
| Market Cap | 139.15M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.11 | |
| Beta | 1.09 |
Today's Price Range 19.2919.56 | 52W Range 12.1320.18 | 5 Year PE Ratio Range 5.0022.60 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 2.31% | ||
| 1 Month | 41.81% | ||
| 3 Months | 20.93% | ||
| 6 Months | 12.54% | ||
| 1 Year | 9.19% | ||
| 3 Years | 1.30% | ||
| 5 Years | -8.07% | ||
| 10 Years | 8.05% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 4.89 | |||
ROE last 12 Months | 7.30 | |||
ROA (5Y Avg) | 2.64 | |||
ROA last 12 Months | 5.57 | |||
ROC (5Y Avg) | 13.60 | |||
ROC last 12 Months | 5.58 | |||
Return on invested Capital Q | 1.02 | |||
Return on invested Capital Y | 6.61 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 1.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 12.20 | ||||
| 0.80 | ||||
| 1.66 | ||||
| 7.30 | ||||
| 14.00 | ||||
| 2.51 | ||||
| 0.85 | ||||
| 22.84 | ||||
| 111.93M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.80 | ||||
| 8.00 | ||||
| 0.18 | ||||
| 0.25 | ||||
| 59.90 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 47.80 | ||||
| 21.20 | ||||
| 30.40 | ||||
| 19.00 | ||||
| 13.54 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 72.57M | ||||
| 11.10 | ||||
| -0.75 | ||||
| 3.93 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | 0.16 | - |
| Q03 2023 | - | 0.55 | - |
| Q02 2023 | - | 0.32 | - |
| Q03 2022 | - | 0.32 | - |
| Q02 2022 | - | 0.57 | - |
| Q03 2021 | - | 0.54 | - |
| Q02 2021 | - | 0.44 | - |
| Q01 2021 | - | 0.36 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 13.80K |
| Shares Outstanding | 7.15K |
| Shares Float | 6.90M |
| Trades Count | 337 |
| Dollar Volume | 269.24K |
| Avg. Volume | 23.56K |
| Avg. Weekly Volume | 16.93K |
| Avg. Monthly Volume | 33.26K |
| Avg. Quarterly Volume | 20.49K |
Fonar Corporation (NASDAQ: FONR) stock closed at 19.47 per share at the end of the most recent trading day (a 0.52% change compared to the prior day closing price) with a volume of 13.80K shares and market capitalization of 139.13M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 424 people. Fonar Corporation CEO is Timothy R. Damadian.
The one-year performance of Fonar Corporation stock is 9.19%, while year-to-date (YTD) performance is 16.24%. FONR stock has a five-year performance of -8.07%. Its 52-week range is between 12.1301 and 20.18, which gives FONR stock a 52-week price range ratio of 91.18%
Fonar Corporation currently has a PE ratio of 12.20, a price-to-book (PB) ratio of 0.80, a price-to-sale (PS) ratio of 1.66, a price to cashflow ratio of 7.30, a PEG ratio of -, a ROA of 5.57%, a ROC of 5.58% and a ROE of 7.30%. The company’s profit margin is 13.54%, its EBITDA margin is 30.40%, and its revenue ttm is $72.57 Million , which makes it $11.10 revenue per share.
Of the last four earnings reports from Fonar Corporation, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Fonar Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Fonar Corporation is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Fonar Corporation stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Fonar Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Fonar Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 11.42, ATR14 : 0.66, CCI20 : 67.06, Chaikin Money Flow : 0.13, MACD : 1.34, Money Flow Index : 63.26, ROC : 15.09, RSI : 71.53, STOCH (14,3) : 78.96, STOCH RSI : 0.17, UO : 53.82, Williams %R : -21.04), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Fonar Corporation in the last 12-months were:
Fonar Corporation
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and Management of diagnostic imaging centers, which generates a vast majority of the revenue. The company's areas of operations are principally in the United States. It also exports to the United Arab Emirates, England, and Germany.
CEO: Timothy R. Damadian
Telephone: +1 631 694-2929
Address: 110 Marcus Drive, Melville 11747, NY, US
Number of employees: 424
